Oncotarget

Research Papers:

Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells

Feng Ge, Haishi Zhang, Daisy Dandan Wang, Linda Li and Peter Ping Lin _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:27049-27064. https://doi.org/10.18632/oncotarget.4819

Metrics: PDF 1317 views  |   HTML 1370 views  |   ?  


Abstract

Feng Ge1,*, Haishi Zhang2,*, Daisy Dandan Wang3, Linda Li3, Peter Ping Lin3

1Department of Thoracic Surgery, Capital Medical University School of Oncology and Chaoyang Hospital, Beijing, China

2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

3Cytelligen, San Diego, California, USA

*These authors have contributed equally to this study

Correspondence to:

Peter Ping Lin, e-mail: plin@cytelligen.com

Keywords: CTC and DTC subtypes, iFISH, subtraction enrichment, cytokeratin (CK) 18, in situ phenotyping and karyotyping

Received: June 29, 2015     Accepted: July 17, 2015     Published: July 29, 2015

ABSTRACT

Conventional strategy of anti-EpCAM capture and immunostaining of cytokeratins (CKs) to detect circulating tumor cells (CTCs) is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs. In this study, a novel integrated cellular and molecular approach of subtraction enrichment (SE) and immunostaining-FISH (iFISH) was successfully developed. Both large or small size CTCs and circulating tumor microemboli (CTM) in various biofluid samples including cerebrospinal fluid (CSF) of cancer patients and patient-derived-xenograft (PDX) mouse models were efficiently enriched and comprehensively identified and characterized by SE-iFISH. Non-hematopoietic CTCs with heteroploid chromosome 8 were detected in 87–92% of lung, esophageal and gastric cancer patients. Characterization of CTCs performed by CK18-iFISH showed that CK18, the dual epithelial marker and tumor biomarker, was strong positive in only 14% of lung and 24% of esophageal CTCs, respectively. Unlike conventional methodologies restricted only to the large and/or both EpCAM and CK positive CTCs, SE-iFISH enables efficient enrichment and performing in situ phenotypic and karyotypic identification and characterization of the highly heterogeneous CTC subtypes classified by both chromosome ploidy and the expression of various tumor biomarkers. Each CTC subtype may possess distinct clinical significance relative to tumor metastasis, relapse, therapeutic drug sensitivity or resistance, etc.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4819